Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group.

Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group.

Show other versions (1)

<h4>Background</h4>The WHO recommended 1200mg/day of fluconazole (FCZ) in the induction phase of cryptococcal meningitis (CM) in HIV prior to 2018 in regions where amphotericin-B (AMB) was unavailable. A 2-stage AMB-controlled, dose-escalation study to determine the maximum tolerated dos...

Full description

Bibliographic Details
Main Authors: Umesh G Lalloo, Lauren Komarow, Judith A Aberg, David B Clifford, Evelyn Hogg, Ashley McKhann, Aggrey Bukuru, David Lagat, Sandy Pillay, Vidya Mave, Khuanchai Supparatpinyo, Wadzanai Samaneka, Deborah Langat, Eduardo Ticona, Sharlaa Badal-Faesen, Robert A Larsen, ACTG A5225 Team
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0281580

Internet

https://doi.org/10.1371/journal.pone.0281580

Similar Items